A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation

Cancer type: Breast cancer

Phase: II

Principal Investigator: Eikesdal Hans Petter

Country: NO

Keywords: Norway, Bergen

Status: Inclusion completed

Link to